Motivation to succeed, mission to reduce disability

BioAxone is committed to the creation and development of drug candidates to transform the lives of patients afflicted with neurotrauma or neurovascular disorders.

Our orally available ROCK2 inhibitor is licensed to Neurelis. NRL-1049 (previously BA-1049) is drug candidate to treat cerebral cavernous malformation (CCM) and other diseases of blood brain barrier dysfunction.

BioAxone has a Phase 3 Rho inhibitor (BA-210) and a preclinical drug BA-434 targeting axon regeneration and treatment of spinal cord injury available for licensing.